We wanted to characterize the use of Helicobacter pylori eradication therapy in Denmark (5,227,862 inhabitants).
All H. pylori eradication treatments from a nationwide database including all redeemed drug prescriptions in the period January 1994 to June 1996 were identified.
So were all outpatients receiving a drug prescription for H. pylor eradication.
We recorded 34,582 prescriptions for H. pylori eradication therapy given to 28,784 patients.
The incidence of new consumers was 220 per 105 inhabitants per year. with a maximum at 70-79 years of age.
Eighty-six per cent of the patients had only one treatment course.
In 16% of the eradication therapies. nonsteroid anti-inflammatory drugs had been prescribed within the previous 3 months, and 45% had an anti-ulcer drug prescribed 1-12 months after the H. pylori eradication therapy.
Consumption of antibiotics used for H. pylori eradication accounted for 1.4% of the total consumption of antibiotics.
The incidence of H. pylori eradication therapy was fairly stable but with changes in the pattern of drug regimens used.
Anti-ulcer drugs were often given after H. pylori eradication therapy, suggesting an inappropriate use of treatment.
Mots-clés Pascal : Gastrite, Bactériose, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bactérie, Incidence, Chimiothérapie, Antibactérien, Antisécrétoire, Eradication, Evolution, Prescription médicale, Epidémiologie, Homme, Danemark, Europe, Appareil digestif pathologie, Estomac pathologie
Mots-clés Pascal anglais : Gastritis, Bacteriosis, Infection, Helicobacter pylori, Spirillaceae, Spirillales, Bacteria, Incidence, Chemotherapy, Antibacterial agent, Antisecretory agent, Eradication, Evolution, Medical prescription, Epidemiology, Human, Denmark, Europe, Digestive diseases, Gastric disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0432196
Code Inist : 002B30A01A2. Création : 25/01/1999.